Semaglutide and Heart Disease Risk: Benefits Extend Beyond Weight Loss

What the SELECT Trial Data Demonstrated

Semaglutide and heart disease risk reduction cannot be explained entirely by patients losing weight while taking the medication. Researchers published an analysis in the European Heart Journal evaluating 17,604 participants with overweight or obesity from the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) clinical trial. Participants in the trial did not have diabetes at baseline.

Half of the trial participants received semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, while the other half received a placebo. Patients taking semaglutide experienced a 20 percent lower rate of serious cardiovascular events, including heart attack, stroke, and cardiovascular death.

Measured Risk Factors Explain Half the Protection

Standard metabolic and clinical risk factors accounted for no more than half of the recorded decrease in heart disease events. The research team, led by Professor Helen Colhoun from the University of Edinburgh, tracked changes in body weight, waist circumference, and blood pressure over two years.

Investigators also monitored blood test markers reflecting cholesterol levels, kidney function, inflammation, and blood sugar control. When analyzed individually or in combination, these measurable improvements failed to explain the full 20 percent event reduction observed in treated patients.

Alternate Mechanisms for Cardiovascular Health

Researchers suggest that semaglutide functions directly on vascular tissues rather than relying strictly on adipose mass reduction. Proposed alternate pathways include anti-inflammatory actions not detected by the trial's blood tests, as well as direct protective actions on heart muscle and the endothelial lining of blood vessels.

Professor Subodh Verma from the University of Toronto noted in an accompanying editorial that the cardiovascular findings expand how clinicians evaluate GLP-1 receptor agonists. Researchers conclude the drug should be viewed as a medication for reducing cardiovascular disease risk, rather than exclusively as an intervention for weight management.

Trial Limitations and Data Collection Caveats

The study authors noted several limitations that require careful interpretation before translating findings to clinical care. The SELECT trial gathered patient data during the coronavirus disease 2019 (COVID-19) pandemic, which introduced disruption to routine in-person data collection schedules.

Statistical calculations relied on risk estimations rather than direct mechanistic measurements inside tissues. Some trial participants also lost weight due to factors like physical frailty, an outcome that historically elevates rather than reduces cardiovascular disease risks.

Clinical Next Steps for Cardiovascular Risk

Individuals assessing semaglutide and heart disease risk should review their overall cardiovascular health history with their physician. Because the drug shows benefit independent of total scale weight lost, clinical evaluation may extend beyond standard weight goals.

Patients should consult a licensed healthcare professional to evaluate whether semaglutide aligns with their cardiovascular risk profile and metabolic health objectives.